scholarly journals Re: ‘Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults’ by Pertzov et al.

2019 ◽  
Vol 25 (12) ◽  
pp. 1570-1571 ◽  
Author(s):  
X. Zhou ◽  
G. Tang
2019 ◽  
Vol 16 (10) ◽  
pp. 1130-1137
Author(s):  
Hayrettin Ozan Gulcan ◽  
Serkan Yigitkan ◽  
Ilkay Erdogan Orhan

High cholesterol and triglyceride levels are mainly related to further generation of lifethreating metabolism disorders including cardiovascular system diseases. Therefore, hypercholesterolemia (i.e., also referred to as hyperlipoproteinemia) is a serious disease state, which must be controlled. Currently, the treatment of hypercholesterolemia is mainly achieved through the employment of statins in the clinic, although there are alternative drugs (e.g., ezetimibe, cholestyramine). In fact, the original statins are natural products directly obtained from fungi-like molds and mushrooms and they are potent inhibitors of hydroxymethylglutaryl-CoA reductase, the key enzyme in the biosynthesis of cholesterol. This review focuses on the first identification of natural statins, their synthetic and semi-synthetic analogues, and the validation of hydroxymethylglutaryl-CoA reductase as a target in the treatment of hypercholesterolemia. Furthermore, other natural products that have been shown to possess the potential to inhibit hydroxymethylglutaryl-CoA reductase are also reviewed with respect to their chemical structures.


2009 ◽  
Vol 12 (3) ◽  
pp. 337 ◽  
Author(s):  
John D. Clements ◽  
Fakhreddin Jamali

Purpose. Inflammation in forms of rheumatoid and experimental arthritis cause not only joint pain but also excessive cardiovascular mortality. The condition also reduces response to calcium channel and β-adrenergic (β1-AR) antagonists. For calcium channel inhibitors, the reduced response is shown to be due to the reduced expression of target proteins. Hydroxymethylglutaryl CoA reductase inhibitors (statins) restore response to propranolol and verapamil. We tested the effect of adjuvant arthritis on the norepinephrine (NE) transporter (NET) density since altered sympathetic nervous system innervation has been observed in rheumatoid arthritis. Methods. Male Sprague–Dawley rats were divided into the following groups: Healthy/Placebo, Healthy/Statin, Pre-AA/Placebo, and Pre-AA/Statin (n=7-8/group). On Day 0, to the Pre-AA and Healthy groups, was injected Mycobacterium butyricum or saline, respectively. On Days 4-8, Statin and Placebo groups received either pravastatin (6 mg/kg) or placebo twice daily, respectively. On day 8, heart and blood samples were collected. The density of NET and 1-AR in heart homogenate; NE in plasma and heart and inflammatory mediators (nitrite and interferon-γ) in serum were determined. Results. Inflammation was associated with a significant reduction in both β1-AR and NET density with a positive correlation between the two proteins (r=0.978, p


2019 ◽  
Vol 25 (12) ◽  
pp. 1572-1573
Author(s):  
B. Pertzov ◽  
N. Eliakim-Raz ◽  
H. Atamna ◽  
A.Z. Trestioreanu ◽  
D. Yahav ◽  
...  

1993 ◽  
Vol 59 (1) ◽  
pp. 51-57 ◽  
Author(s):  
Rosa Anna Rabini ◽  
Mauro Polenta ◽  
Roberto Staffolani ◽  
Massimo Tocchini ◽  
Roberto Signore ◽  
...  

2016 ◽  
Vol 11 (38) ◽  
pp. 1-8
Author(s):  
Susana Silva ◽  
Nuno Monteiro

Objetivo: Determinar se existe relação entre o uso de estatinas e a incidência de Diabetes Melittus tipo 2 (DM2). Métodos: Foram realizadas pesquisas nas bases de dados National Guidelines Clearinghouse, Cochrane Lybrary, Trip database, PubMed e MedLine utilizando os termos MeSH “Diabetes Mellitus Type 2” e “Hydroxymethylglutaryl-CoA Reductase Inhibitors” (inibidores da HMG-CoA redutase). Foram incluídas revisões sistemáticas e meta-análises e ensaios clínicos aleatorizados e controlados que avaliassem a incidência de DM2 em utilizadores de estatinas, quando comparado com placebo. Resultados: Foram selecionados 10 artigos (1 meta-análise e 9 ensaios clínicos aleatorizados e controlados). A evidência sugere que o uso de estatinas está associado a um aumento da incidência de DM2, principalmente com doses elevadas, em relação ao placebo, na maioria dos estudos avaliados. Conclusão: O risco de incidência de DM2 deve ser considerado, especialmente quando da prescrição de estatinas a indivíduos com baixo risco cardiovascular (SOR A), embora os estudos selecionados apresentem algumas limitações (metodologia heterogênea, sendo a maioria observacional).


Author(s):  
Barak Pertzov ◽  
Anca Zalmanovici Trestioreanu ◽  
Noa Eliakim-Raz ◽  
Dafna Yahav ◽  
Leonard Leibovici

Sign in / Sign up

Export Citation Format

Share Document